Epidemiology and factors associated with candidaemia following Clostridium difficile infection in adults within metropolitan Atlanta, 2009-2013

Epidemiology and Infection

Volumn 144, Issue 7, 2016, Pages 1440-1444

  Vallabhaneni, S ^a,b   Almendares, O ^c,d   Farley, M M ^e,f   Reno, J ^b,c,f   Smith, Z T ^b,c   Stein, B ^c,e   Magill, S S ^b   Smith, R M ^b   Cleveland, A A ^b   Lessa, F C ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Georgia Emerging Infections Program   (United States)

^d ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Candidaemia; CDI treatment; Clostridium difficile infection; co infection; severe CDI

Indexed keywords

METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTERIUM IDENTIFICATION; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNGUS IDENTIFICATION; HUMAN; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; YOUNG ADULT; ADOLESCENT; AGED; CLOSTRIDIUM INFECTIONS; COMPLICATION; FEMALE; GEORGIA; MALE; MICROBIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CANDIDA; CANDIDEMIA; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; GEORGIA; HUMANS; LONGITUDINAL STUDIES; MALE; METRONIDAZOLE; MIDDLE AGED; PREVALENCE; RISK FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 84948668047     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268815003027     Document Type: Article

References (13)

1. Lessa FC, et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine 2015; 372: 825-834.
2. Magill SS, et al. Multistate point-prevalence survey of health care-associated infections. New England Journal of Medicine 2014; 370: 1198-208.
3. Bignardi GE. Risk factors for Clostridium difficile infection. Journal of Hospital Infections 1998; 40: 1-15.
4. Wey SB, et al. Risk factors for hospital-acquired candidaemia. A matched case-control study. Archives of Internal Medicine 1989; 149: 2349-53.
5. Nerandzic MM, et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clinical Infectious Diseases 2012; 55: S121-S126.
6. Guastalegname M, et al. Candidaemia subsequent to severe infection due to Clostridium difficile: is there a link? Clinical Infectious Diseases 2013; 57: 772-774.
7. Cleveland AA, et al. Changes in incidence and antifungal drug resistance in candidaemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clinical Infectious Diseases 2012; 55: 1352-1361.
8. Fanfair RN, et al. Racial disparities in candidaemia: results from population-based surveillance in the United States, 2008-2010, no. M-1511. Presented at the 2011 ICAAC, 17-20 September, Chicago.
9. Cohen S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010; 31: 431-455.
10. Lewis BB, et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. Journal of Infectious Diseases. Published online: 28 April 2015. doi:10.1093/infdis/jiv256.
11. Falcone M, et al. Bloodstream infections secondary to Clostridium difficile infection: risk factors and outcomes. Antimicrobial Agents and Chemotherapy 2015; pii: AAC.01927-15.
12. Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrobial Agents and Chemotherapy 2013; 57: 689-96.
13. Russo A, et al. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile. Clininical Microbiology and Infection 2015; pii: S1198-743X(15)00178-0.